Medicina traslacional y fibrilación auricular: ¿qué nuevas terapias tenemos disponibles?

Juan Santiago Serna-Trejos; Stefanya Geraldine Bermúdez-Moyano; Carlos Andrés Castro-Galvis

doi:10.47487/apcyccv.v6i2.484

Autores/as

Juan Santiago Serna-Trejos Universidad ICESI, Cali, Colombia. https://orcid.org/0000-0002-3140-8995
Stefanya Geraldine Bermúdez-Moyano Unidad de Cuidado Intensivo, Hospital Universitario del Valle, Cali, Colombia. https://orcid.org/0000-0002-2259-6517
Carlos Andrés Castro-Galvis Pontificia Universidad Javeriana Cali, Cali, Colombia. https://orcid.org/0000-0002-8314-4506

DOI:

https://doi.org/10.47487/apcyccv.v6i2.484

Descargas

Los datos de descarga aún no están disponibles.

Referencias

Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193.

Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res. 2017;120(9):1501-1517. doi: 10.1161/CIRCRESAHA.117.309732.

Sagris M, Vardas EP, Theofilis P, Antonopoulos AS, Oikonomou E, Tousoulis D. Atrial Fibrillation: Pathogenesis, Predisposing Factors, and Genetics. Int J Mol Sci. 2021;23(1):6. doi: 10.3390/ijms23010006.

Wiedmann F, Frey N, Schmidt C. Two-Pore-Domain Potassium (K2P-) Channels: Cardiac Expression Patterns and Disease-Specific Remodelling Processes. Cells. 2021;10(11):2914. doi: 10.3390/cells10112914.

Paasche A, Wiedmann F, Kraft M, Seibertz F, Herlt V, Blochberger PL, et al. Acute antiarrhythmic effects of SGLT2 inhibitors–dapagliflozin lowers the excitability of atrial cardiomyocytes. Basic Res Cardiol. 2024;119(1):93-112. doi: 10.1007/s00395-023-01022-0.

Wiedmann F, Beyersdorf C, Zhou XB, Kraft M, Paasche A, Jávorszky N, et al. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Cardiovasc Res. 2022;118(7):1728-1741. doi: 10.1093/cvr/cvab177.

Bai DL, Chen WZ, Bo YX, Dong YL, Kang AL, Sun WK, et al. Discovery of N-(3,5- bis(1-pyrrolidylmethyl)-4-hydroxybenzyl)-4- methoxybenzenesulfamide (sulcardine) as a novel anti-arrhythmic agent. Acta Pharmacol Sin. 2012;33(9):1176-86. doi: 10.1038/aps.2012.119.